Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases

You may be eligible if

• DISEASE CHARACTERISTICS:
• Radiographically, histologically, or cytologically confirmed brain metastases with histologically or cytologically confirmed primary malignancy except the following:
• * Small cell lung cancer, germ cell tumors, and lymphomas
• No leptomeningeal metastases
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 70-100%
• Life expectancy:
• Not specified
• Hematopoietic:
• Hemoglobin at least 10 g/dL
• WBC at least 2,000/mm3
• Platelet count at least 75,000/mm3
• Hepatic:
• Bilirubin no greater than 2.0 mg/dL
• ALT and AST no greater than 3 times upper limit of normal
• Renal:
• Creatinine no greater than 2.0 mg/dL
• Pulmonary:
• Forced vital capacity and forced expiratory volume at least 50% of normal in patients with significant intrathoracic tumor involvement, chronic obstructive pulmonary disease, interstitial lung disease, or pulmonary embolism
• Resting and exercise oxygen saturation at least 90% on room air
• Other:
• No other concurrent active malignancy from a second histologic site
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior biologic therapy or immunotherapy for brain metastases
• At least 28 days since prior investigational biologic therapy
• Chemotherapy:
• No prior chemotherapy for brain metastases
• No chemotherapy for brain metastases for at least one month following radiation therapy
• At least 7 days since prior chemotherapy for primary tumor or extracranial metastases
• No planned chemotherapy during radiation therapy
• Endocrine therapy:
• No prior hormonal therapy for brain metastases
• Prior or concurrent corticosteroid therapy allowed
• Radiotherapy:
• No prior whole brain radiotherapy for brain metastases
• No prior stereotactic radiosurgery for brain metastases
• Surgery:
• Prior surgery allowed for brain metastases if at least one measurable lesion remains
• Other:
• At least 28 days since prior investigational drug or device
• No prior RSR13